Ketone Ester Supplements and Aging: What the TAKEOFF Trial Is Actually Testing
What Happened
A University of Connecticut story published in September 2026 describes a clinical trial testing whether a ketone ester supplement can improve what researchers call "health span" in older adults who are starting to show early signs of frailty. The coverage leads with one participant who was leg pressing 203 pounds (92 kg) by the end of the study, and another who reported sharper thinking and better energy during it. Those details are the kind that travel. The parts that decide what the trial actually means are less quoted, so we are going to lay them out.
The short version: this is a well-designed, still-running study with no published results, and everyone involved says so on the record. The official coverage states plainly that neither the participants nor the researchers know who received the supplement, and that "researchers don't yet know whether ketone supplementation will produce those benefits in this population." That sentence is the story for anyone deciding whether to buy ketone esters this month.
What the Trial Actually Is
The study has a name, a registry number, and a public protocol — which means none of this has to be taken on faith. It is the TAKEOFF trial (Targeting Aging With a Ketone Ester for Function in Frailty), registered as NCT06645847 on ClinicalTrials.gov. The registered design:
- Design: randomized, double-blind, placebo-controlled, parallel-group pilot study. The registry lists the phase as "Not Applicable" — this is an early-stage study, not a pivotal trial.
- Participants: adults 65 and older who are "pre-frail" — slowing down physically but not yet meeting frailty criteria. Minimum body weight 50 kg; participants must pass a gait speed screen at enrollment.
- Enrollment target: 180 people across three sites — the Buck Institute for Research on Aging (Novato, California), UConn Health (Farmington, Connecticut), and Ohio State University (Columbus, Ohio). The trial is coordinated by the San Francisco Coordinating Center.
- Intervention: a ketone ester, named in the registry as C8 ketone di-ester (chemical name bis-octanoyl-(R)-1,3-butanediol), formulated as a dietary supplement. The placebo is non-ketogenic canola oil, matched to the same dosing schedule.
- Dosing: a four-week ramp — 12.5 g per day for week one, 25 g per day for week two, 37.5 g per day split into two doses for week three, then 50 g per day split into two doses for the remaining 17 weeks. Total study duration is 20 weeks.
- Principal investigators: John Newman, MD, PhD (Buck Institute), Jeff Volek, PhD (Ohio State), and Jenna Bartley, PhD (UConn Health).
- Timeline: the study started in February 2025. Primary completion is estimated for December 2027, with full completion estimated April 2028.
On outcomes, the two public accounts differ slightly and it is worth saying so rather than picking one. The UConn release describes the primary outcome across all three sites as leg press strength, with secondary measures covering gait speed, walking endurance, cognitive tests and quality of life. The September 2026 coverage describes a composite "vigor-frailty" score combining physical and cognitive function. The registry record is the authoritative source for the endpoint list, and it also notes that Volek's lab is running muscle biopsies at baseline and after supplementation plus MRIs to detect changes in muscle size, while the Buck site is evaluating whether routine clinical biomarkers — insulin, C-reactive protein, cystatin and natriuretic peptide — can work as outcome measures in future aging research.
What This Study Does Not Tell You
Four things, and they matter more than the headline.
There are no results. Not preliminary, not interim. Data collection runs into 2027. Nothing in the coverage reports an effect of ketone esters on any aging measure in humans, because there is nothing to report yet.
The participant stories cannot be attributed to the supplement. The study is blinded, which means the man who hit a 203-pound leg press and the participant who felt mentally sharp do not know whether they received the ketone ester or the canola oil. The coverage says this directly: "Whether the supplement she received had anything to do with those experiences is something neither Donnelly nor the researchers know." Anecdotes from a blinded trial are not weak evidence — they are not evidence about the supplement at all.
It is a pilot. The registry lists it as a pilot study with 180 participants. That scale can establish safety, feasibility and a signal worth chasing. It cannot establish that ketone supplementation preserves strength or cognition in older adults, and the investigators are not claiming it does.
Prior work established safety and feasibility, not benefit. The coverage notes that earlier studies "helped establish the safety and feasibility of ketone ester supplementation in older adults, but clinical data on its ability to improve health span remain limited." That is a meaningful distinction and an easy one to lose in the retelling.
Why This Is Not the Same Question as Eating Keto
This is the part our readers will care about most, and it is the part the coverage makes clearest without meaning to.
Trial participants are not put on a ketogenic diet. The registry requires them to maintain their habitual dietary intake, exercise and medication use. Bartley puts it plainly in the UConn release: "We actually want them doing exactly what they normally do." Her stated reason for using a supplement rather than a diet is adherence — "There are generally no cheat days in the keto diet and adherence is difficult for many people" — and the hope that supplement findings would be "translatable to more of the population."
So the trial is testing whether raising ketone levels through a supplement changes anything, in people whose plates did not change. That is a different question from whether a low-carbohydrate diet does anything — the boundary our keto vs low-carb guide maps for eaters — and the two do not substitute for each other. If this trial reports a benefit, the honest reading is "ketone ester supplementation did this" — not "keto works for aging," and not "you can skip the diet." If it reports nothing, that says nothing about dietary carbohydrate either. Ketones are what the body makes when carbohydrate availability drops and it runs on fat instead — the substrate shift our what-is-keto guide walks through — as the coverage describes. A supplement delivers the molecule without the metabolic state.
That distinction is also the reason we are covering this at all. We price food from a verified USDA database; we do not sell or evaluate supplements. But the gap between "a molecule was elevated" and "a diet changed" is exactly the kind of thing that gets flattened in health headlines, and it is worth keeping the two separate in your own head. For anyone who wants the food side of the question, the arithmetic is already settled. From our verified library, per 100 g: canned tuna in oil is 0.0 g net carbs with 29.13 g protein (FDC #173708), roasted turkey breast 0.0 g with 22.16 g protein (FDC #171501), butter 0.06 g (FDC #173410), grated parmesan 1.37 g with 20.0 g protein (FDC #173452), a hard-boiled egg 1.12 g (FDC #173424), cooked bacon 1.35 g (FDC #167914), avocado 1.83 g with 485 mg potassium (FDC #171705), and cheddar 3.37 g (FDC #173414). A full plate of two large hard-boiled eggs (about 100 g), a 28 g slice of cheddar, 100 g of avocado and 100 g of tuna comes to roughly 3.89 g of net carbs for the entire meal — our arithmetic on those records. No supplement required to get there.
The Disclosure Worth Carrying Forward
The UConn release includes a conflict-of-interest statement, and it is not boilerplate. Newman and Stubbs own stock in BHB Therapeutics Ltd, the company providing the product being studied, and are inventors on patents relating to that product. The Buck Institute holds an ownership interest in BHB Therapeutics. Bartley and Volek report no relevant financial relationships. None of that invalidates the trial — the registry design is blinded and placebo-controlled, which is precisely how you guard against it — but it is the kind of detail readers deserve alongside the participant anecdotes, and we would rather state it than leave it in a footnote somewhere else.
Source Box
Primary coverage: Jennifer Walker, University of Connecticut, "Ketone supplement trial tests whether it can slow aging in older adults," Medical Xpress, September 2026 — the source for all quotes, participant details and the team's own statements of uncertainty. Institutional release: University of Connecticut, "UConn to Participate in First Ever Clinical Trial of Ketogenic Supplements and Healthy Aging," UConn Today — source for the dosing rationale quotes, the primary outcome as leg press strength, the muscle biopsy and MRI procedures, and the conflict-of-interest disclosure. Trial registration: NCT06645847, Targeting Aging With a Ketone Ester for Function in Frailty (TAKEOFF), ClinicalTrials.gov — source for the design, enrollment criteria, dose schedule, sites, timeline and outcome measures. Study listing: UConn Center on Aging, Our Research — source for the enrollment end date. Evidence grade: ongoing randomized, double-blind, placebo-controlled pilot trial; no results published as of this writing. Nothing here is medical advice, and this page is not a recommendation to use or avoid ketone ester supplements. External links are provided for verification.
Do ketone ester supplements slow aging?
Nobody knows, and this trial has not answered it. TAKEOFF (NCT06645847) is a 20-week, blinded, placebo-controlled pilot in 180 adults aged 65 and older, and data collection runs into 2027 with primary completion estimated for December 2027. The researchers state on the record that they do not yet know whether ketone supplementation will produce benefits in this population. Earlier studies in older adults established safety and feasibility of ketone ester supplementation — not benefit.
Is taking a ketone ester the same as following a ketogenic diet?
No, and the trial design shows the difference. TAKEOFF participants are required to maintain their habitual diet, exercise and medication routine, and the lead investigator's stated reason for using a supplement is that adherence to a strict diet is difficult — "There are generally no cheat days in the keto diet." A supplement raises ketone levels without restricting carbohydrate; a ketogenic diet produces ketones by restricting it. If this trial finds an effect, it will be evidence about the supplement, not about the diet.
Should I take ketone esters based on this news?
That is not something this page can answer, and we would not try. We price food from USDA data; we do not evaluate supplements, and nothing here is medical advice. Two factual points are worth having: the registry notes that both the ketone ester and the placebo oil can cause gastrointestinal side effects in some people, and the protocol allows the research team to adjust dosing for that reason. Anyone weighing a supplement — particularly an older adult managing other conditions or medications — should work that through with a qualified health professional rather than a news story.